Phase 2 N=50 Randomized Double-blind Treatment

N-Acetyl Cysteine in Trichotillomania

Trichotillomania

Bottom Line

View on ClinicalTrials.gov: NCT00354770 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jan 2014

Primary outcome: Primary: Massachusetts General Hospital Hairpulling Scale — 17.6; 16.7; 10.4; 16.0 units on a scale

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: Placebo (Drug); N-Acetyl Cysteine (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: University of Chicago
Primary completion: Sep 2008

Outcome Measures

Outcome	Result	p-value
PRIMARY Massachusetts General Hospital Hairpulling Scale	17.6; 16.7; 10.4; 16.0	—

Summary

This is a 12-week, double-blind study of N-Acetyl Cysteine in the treatment of trichotillomania

Eligibility Criteria

Inclusion Criteria

men and women age 18-65;
current DSM-IV trichotillomania

Exclusion Criteria

unstable medical illness;
history of seizures;
myocardial infarction within 6 months;
current pregnancy or lactation, or inadequate contraception in women of childbearing potential;
any thoughts of suicide;
lifetime history of DSM-IV bipolar disorder type I, dementia, or schizophrenia or any other DSM-IV psychotic disorder;
previous treatment with N-Acetyl Cysteine;
treatment with investigational medication or depot neuroleptics within 3 months, with fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study baseline;
9) diagnosis of asthma

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00354770). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.